サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1726347

細胞リプログラミングの世界市場：市場規模・シェア・動向分析 (技術別・用途別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

Cell Reprogramming Market Size, Share & Trends Analysis Report By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
細胞リプログラミングの世界市場：市場規模・シェア・動向分析 (技術別・用途別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年04月25日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞リプログラミング市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の細胞リプログラミングの市場規模は、2025年から2030年にかけて8.55%のCAGRを記録し、2030年には6億6,420万米ドルに達すると推定されています。

がん研究における細胞リプログラミングの採用増加や細胞リプログラミングに対する注目の高まりなどの要因が市場成長を促進すると予測されています。さらに、主要企業間の共同研究やパートナーシップの重視が市場成長を後押しすると予測されています。mRNAリプログラミング技術の進歩により、体組織を用いた臨床グレードのヒトiPS細胞の迅速かつ安全で効率的な作製が可能になります。さらに、mRNAはサイズが小さいため、トランスフェクションプロセスは他の初期化ベクターよりも簡単です。リプログラミングが困難なサンプルを利用する場合、mRNAリプログラミングはリプログラミング効率を1％向上させます。

さらに、この方法は体組織から高品質のヒトiPS細胞をより迅速かつ安全に作製できるため、mRNA初期化技術の需要が高まっています。さらに、ヒト幹細胞をナイーブな状態に再プログラムする能力もあり、最も初期の発生段階を再現できます。例えば、2022年3月、バブラハム研究所の研究者たちは、この初期化プロセスを促進する重要な因子を特定しました。この新たな知見は、研究者にとってナイーブ多能性幹細胞の生成を合理化し、迅速化するものです。さらに、細胞の初期化は、政府や公的資金による大きな後押しを受けて成長しています。このような支援は、特に医療への応用の可能性という点で、ヘルスケア分野に様々な利点をもたらすことへの反応です。

さらに、細胞リプログラミングは最近、研究者によって研究室からクリニックへと再配置されています。この変化は、再生医療、疾患モデリング、薬物毒性・創薬に関連する研究など、様々な臨床・学術研究において顕著です。細胞リプログラミングの臨床的有用性は、特に再生医療において顕著です。細胞リプログラミングによる革新的な製品開発を目指した戦略的イニシアチブの増加は、研究・学術機関セグメントの成長によるものです。例えば、California Institute for Regenerative Medicine（カリフォルニア再生医療研究所）は、細胞リプログラミングを臨床に焦点を当てた治療応用に進めるための研究グループに資金を提供しています。

細胞リプログラミング市場レポートハイライト

  • mRNAリプログラミング技術セグメントは、体組織から高品質のヒトiPS細胞を作製する一方で、使いやすさ、スピード、安全性、効率性により、2024年には32.63%の最大収益シェアを占めました。
  • 研究用途セグメントは、2024年に67.30%のシェアを獲得して市場をリードしました。成長を促進する主な要因のひとつは、幹細胞を用いた細胞リプログラミングの分野で進行中の調査です。
  • 研究・学術機関の最終用途セグメントは、2024年に67.30%の売上シェアを占めました。この成長は、再生治療、疾患モデリング、薬物毒性／創薬研究を含む様々な臨床・学術研究イニシアティブにおける細胞リプログラミングの利用によるものです。
  • 北米は2024年に39.69％の売上シェアで世界業界を支配しましたが、これはこの地域の大手企業の存在によるものです。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 市場の変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 技術別のビジネス分析

  • 技術別ダッシュボード
  • 細胞リプログラミング市場：技術別の変動分析
  • センダイウイルス活用型リプログラミング
    • センダイウイルス活用型リプログラミング市場（2018～2030年）
  • mRNAリプログラミング
    • mRNAリプログラミング市場（2018～2030年）
  • エピソームリプログラミング
    • エピソームリプログラミング市場（2018～2030年）
  • その他
    • その他のリプログラミング市場（2018～2030年）

第5章 用途別のビジネス分析

  • 用途別ダッシュボード
  • 細胞リプログラミング市場：用途別の変動分析
  • 研究
    • 研究市場（2018～2030年）
  • 治療
    • 治療市場（2018～2030年）

第6章 最終用途別のビジネス分析

  • 最終用途別のダッシュボード
  • 細胞リプログラミング市場：最終用途別の変動分析
  • 研究・学術機関
    • 研究・学術機関市場（2018～2030年）
  • バイオテクノロジーおよび製薬会社
    • バイオテクノロジー・製薬企業市場（2018～2030年）

第7章 地域別のビジネス分析

  • 地域別ダッシュボード
  • 細胞リプログラミングの市場シェア：地域別（2018～2030年）
  • 北米
    • 北米の細胞リプログラミング市場（2018～2030年）
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州の細胞リプログラミング市場（2018～2030年）
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • アジア太平洋の細胞リプログラミング市場（2018～2030年）
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ラテンアメリカの細胞リプログラミング市場（2018～2030年）
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカの細胞リプログラミング市場（2018～2030年）
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 企業分類
  • 戦略マッピング
  • 企業の市況分析
  • 企業プロファイル/上場企業
    • Thermo Fisher Scientific, Inc.
    • Allele Biotechnology and Pharmaceuticals Inc.
    • ALSTEM
    • STEMCELL Technologies
    • Merck KGaA
    • Bio-Techne
    • REPROCELL Inc.
    • Lonza
    • FUJIFILM Corporation（Fujifilm Cellular Dynamics）
    • Mogrify Limited
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 4 Global Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 5 Global Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 6 Global Cell Reprogramming Market, By Region, 2018 - 2030 (USD Million)
  • Table 7 North America Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 9 North America Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 10 North America Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 11 U.S. Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 14 Canada Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 15 Canada Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 17 Mexico Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 18 Mexico Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 19 Mexico Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 20 Europe Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 22 Europe Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 23 Europe Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 24 UK Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 25 UK Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 26 UK Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 27 Germany Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 28 Germany Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 29 Germany Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 30 France Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 31 France Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 32 France Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 33 Spain Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 34 Spain Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 35 Spain Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 36 Italy Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 37 Italy Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 38 Italy Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 39 Denmark Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 40 Denmark Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 41 Denmark Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 42 Norway Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 43 Norway Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 44 Norway Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 45 Sweden Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 46 Sweden Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 47 Sweden Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 52 China Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 53 China Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 54 China Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 55 Japan Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 56 Japan Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 57 Japan Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 58 India Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 59 India Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 60 India Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 61 South Korea Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 62 South Korea Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 63 South Korea Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 64 Australia Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 65 Australia Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 66 Australia Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 67 Thailand Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 68 Thailand Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 69 Thailand Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 70 Latin America Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 72 Latin America Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 73 Latin America Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 74 Brazil Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 75 Brazil Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 76 Brazil Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 77 Argentina Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 78 Argentina Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 79 Argentina Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 80 MEA Cell Reprogramming Market, By Country, 2018 - 2030 (USD Million)
  • Table 81 MEA Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 82 MEA Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 83 MEA Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 84 South Africa Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 85 South Africa Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 86 South Africa Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 87 UAE Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 88 UAE Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 89 UAE Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 92 Saudi Arabia Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Cell Reprogramming Market, By Technology, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Cell Reprogramming Market, By Application, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Cell Reprogramming Market, By End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Cell Reprogramming market segmentation
  • Fig. 8 Market snapshot
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 PESTEL analysis
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Global cell reprogramming market: Technology outlook and key takeaways
  • Fig. 15 Global cell reprogramming market: Technology movement analysis
  • Fig. 16 Global cell reprogramming market, for sendai virus-based reprogramming, 2018 - 2030 (USD Million)
  • Fig. 17 Global cell reprogramming market, for mRNA reprogramming, 2018 - 2030 (USD Million)
  • Fig. 18 Global cell reprogramming market, for episomal reprogramming, 2018 - 2030 (USD Million)
  • Fig. 19 Global cell reprogramming market, for others, 2018 - 2030 (USD Million)
  • Fig. 20 Global cell reprogramming market: Application outlook and key takeaways
  • Fig. 21 Global cell reprogramming market: Application movement analysis
  • Fig. 22 Global cell reprogramming market, for research, 2018 - 2030 (USD Million)
  • Fig. 23 Global cell reprogramming market, for therapeutic, 2018 - 2030 (USD Million)
  • Fig. 24 Global cell reprogramming market: End-use outlook and key takeaways
  • Fig. 25 Global cell reprogramming market: End-use movement analysis
  • Fig. 26 Global cell reprogramming market, for research & academic institutes, 2018 - 2030 (USD Million)
  • Fig. 27 Global cell reprogramming market, for biotechnology & pharmaceutical companies, 2018 - 2030 (USD Million)
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 Regional outlook, 2022 & 2030
  • Fig. 30 North America cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Key country dynamics
  • Fig. 32 U.S. cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Key country dynamics
  • Fig. 34 Canada cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico Key country dynamics
  • Fig. 36 Mexico cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany Key country dynamics
  • Fig. 39 Germany cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 40 UK Key country dynamics
  • Fig. 41 UK cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 42 France Key country dynamics
  • Fig. 43 France cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy Key country dynamics
  • Fig. 45 Italy cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 46 Spain Key country dynamics
  • Fig. 47 Spain cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark Key country dynamics
  • Fig. 49 Denmark cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 50 Sweden Key country dynamics
  • Fig. 51 Sweden cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 52 Norway Key country dynamics
  • Fig. 53 Norway cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan Key country dynamics
  • Fig. 56 Japan cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 57 China Key country dynamics
  • Fig. 58 China cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 59 India Key country dynamics
  • Fig. 60 India cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 61 Australia Key country dynamics
  • Fig. 62 Australia cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 63 South Korea Key country dynamics
  • Fig. 64 South Korea cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand Key country dynamics
  • Fig. 66 Thailand cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil Key country dynamics
  • Fig. 69 Brazil cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina Key country dynamics
  • Fig. 71 Argentina cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 72 Middle East and Africa cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 73 South Africa Key country dynamics
  • Fig. 74 South Africa cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 75 Saudi Arabia Key country dynamics
  • Fig. 76 Saudi Arabia cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 77 UAE Key country dynamics
  • Fig. 78 UAE cell reprogramming market, 2018 - 2030 (USD Million)
  • Fig. 79 Kuwait Key country dynamics
  • Fig. 80 Kuwait cell reprogramming market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-966-2

Cell Reprogramming Market Growth & Trends:

The global cell reprogramming market size is estimated to reach USD 664.2 million by 2030, registering a CAGR of 8.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. Factors, such as increasing adoption of cell reprogramming in cancer research and growing focus on cell reprogramming, are expected to drive market growth. In addition, emphasis on collaborations and partnerships among key players is anticipated to boost market growth. Advancements in the mRNA reprogramming technique allow rapid, safe, and efficient generation of clinical-grade human iPS cells using somatic tissue. In addition, as mRNA is lower in size, the transfection process is simpler than other reprogramming vectors. When utilizing difficult-to-reprogram samples, mRNA reprogramming improves reprogramming efficiency by 1%.

Furthermore, this method can generate high-quality human iPS cells from somatic tissue more rapidly and safely, which increases the demand for mRNA reprogramming technology. Furthermore, there is the capability to reprogram human stem cells back to a naive state, allowing replication of the earliest developmental stages. For instance, in March 2022, researchers at the Babraham Institute identified key factors facilitating this reprogramming process. This new knowledge streamlines and expedites the generation of naive pluripotent stem cells for researchers. Moreover, cell reprogramming is experiencing growth due to significant government and public funding. This backing is a response to various benefits it offers to the healthcare sector, particularly in terms of its potential applications in medicine.

Furthermore, cell reprogramming has recently been repositioned from the lab to clinic by researchers. This shift is prominent in various clinical & academic research initiatives, encompassing regenerative medicine, disease modeling, and studies related to medication toxicity & drug discovery. The clinical utility of cell reprogramming, especially in regenerative medicine, has been significant. Increased strategic initiatives aimed at innovative product development through cell reprogramming is due to a growth in the research and academic institute segment. For instance, the California Institute for Regenerative Medicine funded research groups to advance cellular reprogramming into therapeutic applications with a clinical focus.

Cell Reprogramming Market Report Highlights:

  • The mRNA reprogramming technology segment held the largest revenue share of 32.63% in 2024, due to the ease of use, speed, safety, and efficiency while generating high-quality human iPS cells from somatic tissue.
  • The research application segment led the market with a share of 67.30% in 2024. One of the main factors driving its growth include ongoing research in the field of cell reprogramming using stem cells.
  • The research & academic institute end-use segment held a revenue share of 67.30% in 2024. The growth is due to usage of cell reprogramming in a various clinical & academic research initiatives, including those involving regenerative therapies, disease modeling, and drug toxicity/drug discovery studies.
  • North America dominated the global industry in 2024, with a revenue share of 39.69%, owing to the presence of key players in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Information Analysis
    • 1.2.2. Market Platform & Data Visualization
    • 1.2.3. Data Validation & Publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Platform & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1:
    • 1.9.2. Objective 2:

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing focus on cell reprogramming
      • 3.2.1.2. Increasing adoption of cell reprogramming in cancer research
      • 3.2.1.3. Emphasis on collaborations and partnerships among key players
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Challenges associated with iPSCs
      • 3.2.2.2. Limited awareness regarding treatment option
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Technology Segment Dashboard
  • 4.2. Cell Reprogramming Market: Technology Movement Analysis
  • 4.3. Sendai Virus-based Reprogramming
    • 4.3.1. Sendai Virus-based Reprogramming Market, 2018 - 2030 (USD Million)
  • 4.4. mRNA Reprogramming
    • 4.4.1. mRNA Reprogramming Market, 2018 - 2030 (USD Million)
  • 4.5. Episomal Reprogramming
    • 4.5.1. Episomal Reprogramming Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Reprogramming Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Cell Reprogramming Market: Application Movement Analysis
  • 5.3. Research
    • 5.3.1. Research Market, 2018 - 2030 (USD Million)
  • 5.4. Therapeutics
    • 5.4.1. Therapeutics Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Cell Reprogramming Market: End-use Movement Analysis
  • 6.3. Research & Academic Institutes
    • 6.3.1. Research & Academic Institutes Market, 2018 - 2030 (USD Million)
  • 6.4. Biotechnology & Pharmaceutical Companies
    • 6.4.1. Biotechnology & Pharmaceutical Companies Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Regional Dashboard
  • 7.2. Cell Reprogramming Market Share by Region, 2018- 2030
  • 7.3. North America
    • 7.3.1. North America Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. U.S. Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Canada Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Mexico Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. UK Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Germany Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. France Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Italy Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Spain Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Denmark Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Sweden Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Norway Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Japan Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. China Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. India Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Australia Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Thailand Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. South Korea Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Brazil Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Argentina Cell Reprogramming Market, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. South Africa Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Saudi Arabia Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. UAE Cell Reprogramming Market, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Kuwait Cell Reprogramming Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis
  • 8.4. Company Profiles/Listing
    • 8.4.1. Thermo Fisher Scientific, Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Allele Biotechnology and Pharmaceuticals Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. ALSTEM
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. STEMCELL Technologies
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Merck KGaA
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Bio-Techne
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. REPROCELL Inc.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Lonza
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. FUJIFILM Corporation (Fujifilm Cellular Dynamics)
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Mogrify Limited
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives